Company Overview
Sera Prognostics, Inc. operates as a specialized entity within the healthcare sector, specifically focusing on the medical devices industry by discovering, developing, and commercializing blood-based biomarker tests along with predictive analytic products and services in the United States. The company has established a distinct niche in women's health by creating non-invasive blood tests, such as the PreTRM test, designed to be administered to pregnant women carrying a single fetus to assist in health monitoring. In terms of scale, Sera Prognostics, Inc. maintains a market capitalization of $72.42M, generates annual revenue of $81,000, and employs a workforce of 71 individuals. These financial metrics indicate that the company operates as a small-cap entity with limited revenue generation relative to its market valuation, suggesting a position typical of early-stage biotechnology or specialized medical device firms that may rely heavily on future product adoption and regulatory approvals to expand its operational footprint.
Financial Health
The company's financial statements for the trailing twelve months (TTM) show a revenue of $81,000, a net income of $-31,928,000, and an EBITDA of $-35,680,000. The substantial disparity between the minimal revenue of $81,000 and the negative net income of $-31,928,000 reveals a cost structure where operating expenses far exceed total sales, a pattern common in research and development phases but indicative of significant burn rates currently. Free cash flow stands at $-17,447,624, which signifies that the company is consuming cash reserves to fund its operations and development activities rather than generating surplus liquidity from its core business activities. When analyzing profitability metrics, the gross margin is reported at -102.5%, the operating margin is -89540.0%, and the profit margin is 0.0%; these figures collectively demonstrate that the company is not profitable on a per-unit basis and that revenue does not cover the direct costs of goods sold or overhead expenses. The balance sheet holds $39.20M in cash against $2.34M in debt, resulting in a debt-to-equity ratio of 3.10, which suggests a leveraged balance sheet where equity is significantly outweighed by debt obligations despite the high cash position. Liquidity is supported by a current ratio of 1.69, indicating that the company possesses sufficient current assets to cover its short-term liabilities without immediate distress. Return on Equity is -51.8% and Return on Assets is -26.1%, metrics that reveal management is currently generating negative returns on the capital invested, reflecting the challenges of sustaining operations without achieving commercial profitability.
Valuation Assessment
Valuation multiples for Sera Prognostics, Inc. present a complex picture where the P/E Ratio (TTM) is N/A due to lack of earnings, while the Forward P/E is listed as -2.76. The difference between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing the stock based on anticipated future earnings that are expected to remain negative or are currently insufficient to justify a traditional earnings multiple. The price-to-book ratio is 0.96, which indicates that the stock is trading slightly below its book value, suggesting the market may be discounting the company's assets or anticipating further operational challenges. Alternative valuation metrics such as the price-to-sales ratio of 894.03 and an EV/EBITDA of -1.00 suggest that the market is valuing the company primarily on its potential rather than current financial performance, as these ratios are heavily skewed by the lack of profitability and high revenue costs. The stock's 52-week high is $4.20 and the 52-week low is $1.37; without a specific current price in the provided facts, the valuation context relies on these bounds to show the volatility range within which the asset has traded over the past year. The beta value is 1.02, meaning the stock's price volatility is slightly higher than the broader market, indicating that the security will likely move in tandem with the market but with marginally increased sensitivity to market swings.
Growth & Income
The growth profile for the company shows a revenue growth year-over-year of -58.3% and an earnings growth year-over-year of N/A. The negative revenue growth indicates a contraction in sales, while the absence of earnings growth data (N/A) implies that earnings are not growing faster than revenue because the company is currently unprofitable, resulting in a contraction of both top-line and bottom-line performance. Regarding income distributions, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not pay dividends to shareholders. Consequently, the company reinvests all available earnings—or rather, all available capital—into growth initiatives, research, and development rather than distributing cash to investors. This non-dividend status combined with negative revenue growth and significant cash burn defines an overall growth and income profile characterized by high risk and zero current yield, typical for pre-commercialization medical device companies attempting to navigate a path to profitability.